0000000000011640

AUTHOR

A. Girlando

showing 3 related works from this author

Stereotactic Radiotherapy for the Treatment of Patients With Oligo-progressive Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth …

2020

Aim This retrospective observational study evaluated the role of hypo-fractionated stereotactic radiotherapy (SRT) in patients with oligo-progressive metastatic renal cell carcinoma (mRCC) treated with first-line oral tyrosine kinase inhibitors (TKI). Data on local control, delay of further progression, and safety are reported. Patients and methods Between January 2010 and December 2016, 28 patients with mRCC who showed oligo-progressive disease while receiving first-line pazopanib were treated with hypofractionated SRT to progressive metastatic sites to delay the change of systemic therapy. First and second progression-free survival (PFS-1 and PFS-2) were recorded, as well as objective res…

OncologyAdultMaleCancer Researchmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentTyrosine-kinase inhibitorDisease-Free SurvivalMetastasisPazopanibRenal cell carcinomaInternal medicinetyrosine kinase inhibitorsmedicinepazopanibmetastasisHumansNeoplasm MetastasisCarcinoma Renal CellProtein Kinase InhibitorsAgedRetrospective Studiesbusiness.industryCarcinomaRenal CellRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseasemetastasis; pazopanib; Renal cell carcinoma; stereotactic radiotherapy; tyrosine kinase inhibitors; Adult; Aged; Carcinoma Renal Cell; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Retrospective StudiesRenal cell carcinomaKidney NeoplasmsRadiation therapyOncologyToxicitystereotactic radiotherapyFemalebusinessTyrosine kinasemedicine.drug
researchProduct

High-dose radiotherapy for oligo-progressive NSCLC receiving EGFR tyrosine kinase inhibitors: Real world data

2020

Background/aim Local ablative treatments for oligo-progressive, EGFR mutated non-small cell lung cancer (mut-NCSLC) may improve long-term disease control and survival. We analyzed the efficacy of hypo-fractionated, high-dose radiation therapy (HDRT), in association with prolonged EGFR tyrosine kinase inhibitors (TKI) in oligo-progressive, EGFR mutant-NSCLC. Patients and methods Progression-free survival-1 (PFS-1, date from initiation of TKI therapy until oligo-progression or death), and progression-free survival-2 (PFS-2, date of focal progression until further progression or death) were evaluated. Results Thirty-six patients were analyzed. The median PFS 1 was 12.5 months. HDHRT consisted …

OncologyCancer Researchmedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentEGFR high-dose radiotherapy Non-small cell lung cancer oligo-progressionEGFRGeneral Biochemistry Genetics and Molecular Biologyoligo-progression03 medical and health sciences0302 clinical medicineNon-small cell lung cancerCarcinoma Non-Small-Cell LungInternal medicinemedicineOverall survivalHumansProtein Kinase InhibitorsRetrospective StudiesPharmacologybusiness.industryEGFR Non-small cell lung cancer high-dose radiotherapy oligo-progressionEGFR; High-dose radiotherapy; Non-small cell lung cancer; Oligo-progressionEGFR Tyrosine Kinase Inhibitorshigh-dose radiotherapyDisease controlProgression-Free SurvivalErbB ReceptorsRadiation therapy030220 oncology & carcinogenesisMutationNon small cellbusinessReal world dataResearch Article
researchProduct

EGFR tyrosine kinase inhibitor therapy continuation with high-dose hypofractionated radiotherapy in EGFR-mutated non-small cell lung cancer (NSCLC) p…

2020

e21580 Background: EGFR tyrosine kinase inhibitors (TKIs) represent the standard first-line therapy for advanced non-small cell lung cancer (NSCLC) patients with activating EGFR mutations. However, despite initial marked responses, tumors invariably develop acquired resistance to TKIs. Oligoprogression is commonly observed during treatment with oncogene-directed therapies, including EGFR TKIs, and refers to patients who experience disease progression only in limited sites as a result of heterogeneous mechanisms of resistance. The use of local ablative treatments for these resistant lesions may extend the duration of TKI therapy and potentially improve long-term disease control and survival…

Hypofractionated RadiotherapyCancer Researchbusiness.industrynon-small cell lung cancer (NSCLC)Diseasemedicine.diseaseEGFR Tyrosine Kinase Inhibitor TherapyEGFR Tyrosine Kinase Inhibitorsrespiratory tract diseasesOncologyEgfr mutationCancer researchMedicineNon small cellbusinessJournal of Clinical Oncology
researchProduct